Irshad Rasha, Raj Nafis, Gabr Gamal A, Manzoor Nikhat, Husain Mohammad
Virology and Oncology Lab, Department of Biotechnology, Jamia Millia Islamia, New Delhi, India.
Medical Mycology Lab, Department of Biosciences, Jamia Millia Islamia, New Delhi, India.
Front Pharmacol. 2022 Oct 12;13:1018974. doi: 10.3389/fphar.2022.1018974. eCollection 2022.
Non-small cell lung cancer (NSCLC) is one of the most malignant types of cancer with soaring incidence rates worldwide, attributed to its heterogeneity and complex etiology. Evidently, alternative anti-cancer therapies comprising traditional medicines and natural products have gained attention for their ability to act as chemopreventive agents with minimal toxicities, either alone or in combination. Accumulating studies have substantiated the inevitability of network pharmacology studies for effectively mapping molecular targets of natural products against multifaceted diseases, including cancer. The 18α-Glycyrrhetinic acid (18α-GA), a triterpenoid found in licorice plants, has shown promising medicinal properties, although, its mechanism of action against NSCLC yet remains elusive. The present study was conducted to explore the anti- NSCLC potential of 18α-GA, employing integrative network pharmacology, molecular docking, and experimental research. Initially, network analysis revealed 181 common targets of 18α-GA in NSCLC as shown in the "compound-target- disease" network employing . Further analyses identified EGFR, AKT1, PI3KR1, MAPK1, IGF1, and SRC as the most crucial hub targets of 18α-GA against NSCLC. Moreover, molecular docking simulations and functional enrichment analyses indicated the involvement of multiple signaling pathways in suppressing NSCLC. Subsequent studies verified the antiproliferative effect of 18α-GA on two NSCLC cancer cell lines, H1299 and A549. Mechanistically, 18α-GA arrested cell cycle at the G1 phase, induced apoptosis, decreased migratory potential, and protein expression levels of EGFR-PI3K/AKT, as examined by flow cytometry, morphological assessment, RT-PCR, and western blot. In conclusion, this study delineates the therapeutic potential and underlying mechanism(s) of 18α-GA as a putative novel drug against NSCLC. However, further studies are warranted to elucidate the complete molecular mechanism(s) using animal models of NSCLC.
非小细胞肺癌(NSCLC)是最具恶性的癌症类型之一,在全球范围内发病率飙升,这归因于其异质性和复杂的病因。显然,包括传统药物和天然产物在内的替代抗癌疗法因其单独或联合使用时作为化学预防剂且毒性最小的能力而受到关注。越来越多的研究证实了网络药理学研究对于有效确定天然产物针对包括癌症在内的多方面疾病的分子靶点的必然性。18α-甘草次酸(18α-GA)是一种在甘草植物中发现的三萜类化合物,已显示出有前景的药用特性,尽管其对NSCLC的作用机制仍不清楚。本研究采用综合网络药理学、分子对接和实验研究来探索18α-GA抗NSCLC的潜力。最初,网络分析显示在使用的“化合物-靶点-疾病”网络中,18α-GA在NSCLC中有181个共同靶点。进一步分析确定表皮生长因子受体(EGFR)、蛋白激酶B1(AKT1)、磷脂酰肌醇-3激酶调节亚基1(PI3KR1)、丝裂原活化蛋白激酶1(MAPK1)、胰岛素样生长因子1(IGF1)和原癌基因酪氨酸蛋白激酶(SRC)是18α-GA对抗NSCLC的最关键核心靶点。此外,分子对接模拟和功能富集分析表明多种信号通路参与抑制NSCLC。随后的研究证实了18α-GA对两种NSCLC癌细胞系H1299和A549的抗增殖作用。从机制上讲,通过流式细胞术、形态学评估、逆转录-聚合酶链反应(RT-PCR)和蛋白质免疫印迹法检测,18α-GA使细胞周期停滞在G1期,诱导细胞凋亡,降低迁移潜能以及EGFR-PI3K/AKT的蛋白表达水平。总之,本研究阐述了18α-GA作为一种潜在的抗NSCLC新型药物的治疗潜力和潜在机制。然而,需要进一步研究以使用NSCLC动物模型阐明完整的分子机制。